Report of Foreign Issuer (6-k)
July 08 2019 - 2:45PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
or
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July, 2019
Commission File Number:
001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrant’s name into English)
4
th
Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F.
Form
20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Mereo BioPharma Group plc
Holding(s) in Company
London,
July
8, 2019
- Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, today provided a regulatory news service (RNS) notification of major holdings
through the London Stock Exchange plc, a copy of which is provided below.
RNS Number : 8439E
Mereo BioPharma Group plc
08 July 2019
TR-1:
Standard form for notification of major holdings
|
|
|
|
|
NOTIFICATION OF MAJOR HOLDINGS
(to be sent to the
relevant issuer
and
to the FCA in Microsoft Word format if possible)
i
|
|
|
|
|
|
|
|
|
1a. Identity of
the issuer or the underlying issuer of existing shares to which voting rights are
attached
ii
:
|
|
Mereo Biopharma Group PLC
|
|
|
|
1b. Please indicate if the issuer is a
non-UK
issuer
(please mark with an “X” if appropriate)
|
|
|
|
|
|
|
|
|
Non-UK
issuer
|
|
|
|
|
|
2. Reason for the notification
(please mark the appropriate box or boxes with an “X”)
|
|
|
|
|
|
|
|
|
An acquisition or
disposal of voting rights
|
|
|
|
|
|
|
An acquisition or
disposal of financial instruments
|
|
|
|
|
|
|
An event changing
the breakdown of voting rights
|
|
|
|
|
|
|
Other (please
specify)
iii
:
No trading in the stock - voting control interest over stock transferred to new manager
|
|
X
|
|
|
|
|
|
|
|
3. Details of person subject to the notification obligation
iv
|
|
|
|
|
Name
|
|
Woodford Investment Management Ltd
|
|
|
|
|
City and country of
registered office (if applicable)
|
|
9400 Garsington Road, Oxford, OX4 2HN, United
Kingdom
|
|
|
|
4. Full name of shareholder(s)
(if different from 3.)
v
|
|
|
|
|
Name
|
|
|
|
|
|
|
City and country of
registered office (if applicable)
|
|
|
|
|
|
|
5. Date on which
the threshold was crossed or reached
vi
:
|
|
05/07/2019
|
|
|
|
|
6. Date on which
issuer notified (DD/MM/YYYY):
|
|
08/07/2019
|
|
|
|
7. Total positions of person(s) subject to the notification obligation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% of voting rights attached to shares (total of 8. A)
|
|
% of voting rights through financial instruments
(total of 8.B 1
+ 8.B 2)
|
|
Total of both in %
(8.A + 8.B)
|
|
Total number of voting rights of
issuer
vii
|
|
|
|
|
|
|
|
|
|
|
|
Resulting situation on the date on which threshold was crossed or reached
|
|
27.56%
|
|
|
|
27.56%
|
|
97,959,622
|
|
Position of previous notification (if
applicable)
|
|
30.46%
|
|
|
|
30.46%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8. Notified
details of the resulting situation on the date on which the threshold was crossed or reached
viii
|
|
A: Voting rights attached to shares
|
|
Class/type of shares
ISIN code (if possible)
|
|
Number of voting rights
ix
|
|
% of voting rights
|
|
|
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
|
|
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
|
|
Direct
(Art 9 of Directive 2004/109/EC)
(DTR5.1)
|
|
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
|
|
GB00BZ4G2K23
|
|
26,999,540
|
|
|
|
27.56%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. A
|
|
26,999,540
|
|
27.56%
|
|
|
|
|
|
|
|
|
|
|
|
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
|
|
Type of financial instrument
|
|
Expiration
date
x
|
|
Exercise/
Conversion
Period
xi
|
|
Number of voting
rights that may be
acquired if the
instrument is
exercised/converted.
|
|
% of
voting
rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. B 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
B 2: Financial Instruments with similar economic effect
according to Art. 13(1)(b) of Directive 2004/109/EC
(DTR5.3.1.1 (b))
|
|
Type of
financial
instrument
|
|
Expiration
date
x
|
|
Exercise/
Conversion
Period
xi
|
|
Physical or
cash
settlement
xii
|
|
Number of
voting
rights
|
|
% of voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8.B.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9.
Information in relation to the person subject to the notification obligation
(please mark the applicable box with an “X”)
|
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or
indirectly an interest in the (underlying) issuer
xiii
|
|
X
|
|
Full
chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling
natural person or legal entity
xiv
(please add additional rows as necessary)
|
|
|
|
|
|
|
|
|
|
|
|
Name
xv
|
|
% of voting rights if it
equals or is higher
than the notifiable
threshold
|
|
% of voting rights
through financial
instruments if it
equals or is higher
than the notifiable
threshold
|
|
Total of both if it
equals or is higher
than the notifiable
threshold
|
|
Woodford Investment Management Ltd
|
|
27.56
|
|
0.00
|
|
27.56
|
|
|
|
|
|
|
|
|
|
10. In case of proxy voting, please identify:
|
|
Name of the proxy holder
|
|
|
|
The number and % of voting rights
held
|
|
|
|
The date until which the voting rights will be held
|
|
|
|
|
|
|
|
|
|
|
|
11.
Additional information
xvi
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Place
of completion
|
|
9400 Garsington Road, Oxford, OX4
2HN, United Kingdom
|
|
|
|
|
Date
of completion
|
|
08/07/2019
|
Further Enquiries
|
|
|
|
|
|
|
Mereo
|
|
|
|
+44 (0)333 023 7300
|
|
Denise Scots-Knight, Chief Executive Officer
|
|
|
|
|
|
Richard Jones, Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker to Mereo )
|
|
|
|
+44 (0)20 7894 7000
|
|
Phil Davies
|
|
|
|
|
|
Will Goode
|
|
|
|
|
|
|
|
|
|
RBC Capital Markets (Joint Broker to Mereo )
|
|
|
|
+44 (0)20 7653 4000
|
|
Rupert Walford
|
|
|
|
|
|
Jamil Miah
|
|
|
|
|
|
|
|
|
|
FTI Consulting (Public Relations Adviser to Mereo )
|
|
|
|
|
|
Simon Conway
|
|
|
|
+44 (0)20 3727 1000
|
|
Brett Pollard
|
|
|
|
|
|
Ciara Martin
|
|
|
|
|
|
|
|
|
|
Burns McClellan (US Public Relations Adviser to Mereo )
|
|
|
|
+01 (0) 212 213 0006
|
|
Lisa Burns
|
|
|
|
|
|
Steve Klass
|
|
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: July 8, 2019
|
|
|
|
|
MEREO BIOPHARMA GROUP PLC
|
|
|
|
|
By:
|
|
/s/ Charles Sermon
|
|
Name:
|
|
Charles Sermon
|
|
Title:
|
|
General Counsel
|
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Apr 2023 to Apr 2024
